glp-1 drug mounjaro analogs, new trend in obesity treatment, become even more effective < Pharma < Article Glp 1 drug hi-res stock

A 24-week phase 2 trial of tesofensine results in a mean weight loss of 4.5%, 9.2% and 10.6% at doses of 0.25 mg, 0.5 mg, and 1.0 mg, respectively, all compared to 2.0% for the placebo group (140)

Marguet D, Baggio L, Kobayashi T, Bernard AM, Pierres M, Nielsen PF, Ribel U, Watanabe T, Drucker DJ, and Wagtmann N

Diabetic retinopathy: current understanding, mechanisms, and treatment strategies

Application of GLP-1R agonists in AD Several studies have reported that GLP-1 agonists could protect brain against various damage in AD models ( Supplementary Table 1 and Table 1 )

Shah BH, Safdar B, Virani SS, Nawaz Z, Saeed SA, Gilani AH

Given the promising preliminary findings with GLP-1RAs, further exploration of this drug class as agents to improve kidney outcomes in people with CKD and T2D is a priority